Promoted Content
Promoted Content

Find Immunology Drugs in Phase I Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABC008

            Therapeutic Area: Immunology Product Name: ABC008

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mass General Brigham Ventures

            Deal Size: $42.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 07, 2021

            Details:

            Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDX-0159

            Therapeutic Area: Immunology Product Name: CDX-0159

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            The Phase 1b study is an open label clinical trial designed to evaluate the safety of a single dose of CDX-0159, a humanized monoclonal antibody and KIT receptor inhibitor, in up to 20 patients with cold contact urticaria who are refractory to antihistamines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACE-1334

            Therapeutic Area: Immunology Product Name: ACE-1334

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Acceleron plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATA188

            Therapeutic Area: Immunology Product Name: ATA188

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2020

            Details:

            Throughout the entire Phase 1a and OLE study, nine of the 16 patients who entered the OLE demonstrated sustained disability improvement (SDI) with ATA188 treatment (seven achieved SDI in the first twelve months and two during the OLE).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Isomyosamine

            Therapeutic Area: Immunology Product Name: MYMD-1

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: MyMD Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger November 12, 2020

            Details:

            Following the merger, the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets, including MYMD-1, a novel drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MGTA-145,Plerixafor

            Therapeutic Area: Immunology Product Name: MGTA-145

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Magenta is developing MGTA-145 to be the first-line therapy for same-day mobilization and collection of hematopoietic stem cells (HSCs) for transplant, to enable successful rebuilding of the blood and immune system.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: EQ001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biocon Limited

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Data will be presented demonstrating that modulation of the CD6-ALCAM pathway with itolizumab improves kidney and skin pathology in mouse models of SLE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ADX-914

            Therapeutic Area: Immunology Product Name: ADX-914

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: OrbiMed Advisors

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 29, 2020

            Details:

            Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company’s groundbreaking tissue-targeted complement regulation platform.